
|Videos|August 13, 2021
Aurion Biotech: Treating endothelial disease with one donor
Author(s)David Hutton, Alex Delaney-Gesing
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Advertisement
Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Neurotrophic keratitis outcomes improve with early, stage-based care
2
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Improved grading scales for oncology drugs causing ocular adverse events
5












































.png)


